PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0189507 ◽  
Author(s):  
Daniel Almeida ◽  
Katia Vianna ◽  
Patrícia Arriaga ◽  
Vittorio Moraschini

2021 ◽  
Author(s):  
Ana Waleska Pessôa Barros ◽  
Pedro Henrique da Hora Sales ◽  
Alessandra de Albuquerque Tavares Carvalho ◽  
Preeyan Patel ◽  
Stephen Porter ◽  
...  

2015 ◽  
Vol 18 (5) ◽  
pp. 937-945 ◽  
Author(s):  
Anke Korfage ◽  
Gerry M Raghoebar ◽  
Suzanne Arends ◽  
Petra M Meiners ◽  
Anita Visser ◽  
...  

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 547.2-547 ◽  
Author(s):  
G. Westhoff ◽  
T.D.O.R.A.C.I. Doerner ◽  
K. Cobarrubias ◽  
T. Dietrich ◽  
A. Zink

2020 ◽  
Vol 30 (2) ◽  
pp. 334-340
Author(s):  
Hamidreza Daneshparvar ◽  
Nasrin Esfahanizadeh ◽  
Reza Vafadoost

Sjögren's syndrome (SS) is a complex autoimmune disease that predominantly affects the exocrine glands, notably the salivary and lacrimal glands, resulting in dryness of the mucosa recognized as xerostomia. Chief oral complications reported by patients consist of high caries rate, burning sensation of the mucosa, early tooth loss, intensified tooth wear and repetitive failure of dental restorations. In particular, due to the decreased salivary flow, conventional removable prostheses might irritate the mucosa and lead to painful ulcerations at the borders of the denture. Implant-supported prostheses offer a unique solution to the difficulties experienced by edentulous patients with Sjögren’s syndrome. This research showed no signs of peri-implantitis or peri-implant mucositis during 7-years following the placement of implants. The present study indicates that successful long-term maintenance of dental implants can be also achieved in SS patients.


VASA ◽  
2008 ◽  
Vol 37 (Supplement 73) ◽  
pp. 26-32 ◽  
Author(s):  
Schlattmann ◽  
Höhne ◽  
Plümper ◽  
Heidrich

Background: In order to analyze the prevalence of Raynaud’s syndrome in diseases such as scleroderma and Sjögren’s syndrom – a meta-analysis of published data was performed. Methods: The PubMed data base of the National Library of Medicine was used for studies dealing with Raynaud’s syndrome and scleroderma or Raynaud’s syndroem and Sjögren’s syndrom respectively. The studies found provided data sufficient to estimate the prevalence of Raynaud’s syndrome. The statistical analysis was based on methods for a fixed effects meta-analysis and finite mixture model for proportions. Results: For scleroderma a pooled prevalence of 80.9% and 95% CI (0.78, 0.83) was obtained. A mixture model analysis found four latent classes. We identified a class with a very low prevalence of 11%, weighted with 0.15. On the other hand there is a class with a very high prevalence of 96%. Analysing the association with Sjögren’s syndrome, the pooled analysis leads to a prevalence of Raynaud’s syndrome of 32%, 95% CI(26.7%, 37.7%). A mixture model finds a solution with two latent classes. Here, 38% of the studies show a prevalence of 18.8% whereas 62% observe a prevalence of 38.3%. Conclusion: There is strong variability of studies reporting the prevalence of Raynaud’s syndrome in patients suffering from scleroderma or Sjögren’s syndrome. The available data are insufficient to perform a proper quantitative analysis of the association of Raynaud’s phenomenon with scleroderma or Sjögren’s syndrome. Properly planned and reported epidemiological studies are needed in order to perform a thorough quantitative analysis of risk factors for Raynaud’s syndrome.


Sign in / Sign up

Export Citation Format

Share Document